Dr. Jung-Min Ahn and Dr. C Michael Gibson Discuss: ASSURE DES – Perioperative antiplatelet therapy in patients with coronary stents before non-cardiac surgery August 31, 2024 Disclosures: TBD
Dr. Moritz Seiffert and Dr. C. Michael Gibson Discuss: Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement In Patients At Low To Intermediate Risk: One Year Outcomes Of The Randomized DEDICATE-DZHK6 Trial April 19, 2024 Disclosures: TBD
Dr. Jung-Min Ahn, Dr. Duk-Woo Park and Dr. C. Michael Gibson Discuss: Preventive PCI Or Medical Therapy Alone For Atherosclerotic Coronary Vulnerable Plaques April 8, 2024 Disclosures: TBD
Dr. David Kandzari and Dr. C. Michael Gibson Discuss: Effect Of Alcohol-mediated Renal Denervation On Blood Pressure In The Presence Of Antihypertensive Drugs: 3-month Primary Results From The Target Bp I Randomized Trial April 8, 2024 Disclosures: TBD
Dr. Rasha Al-Lamee, Dr. Michael Foley and Dr. C. Michael Gibson Discuss: Coronary Sinus Reducer For The Treatment Of Refractory Angina: A Randomised, Placebo-controlled Trial (ORBITA-COSMIC) April 8, 2024 Disclosures: TBD
Dr. David Austin and Dr. C. Michael Gibson Discuss: Preventing Cardiac Damage In Patients Treated For Breast Cancer And Lymphoma: A Phase 3 Randomized, Open Label, Blinded Endpoint, Superiority Trial Of Enalapril To Prevent Anthracycline-induced Cardiotoxicity (PROACT) April 8, 2024 Disclosures: TBD
Dr. Steven Nissen and Dr. C. Michael Gibson Discuss: Outcomes After Technology Assisted Nonprescription Rosuvastatin Administration: The TACTiC Trial April 8, 2024 Disclosures: TBD
Dr. Andre Lamy and Dr. C. Michael Gibson Discuss: Topical Tranexamic Acid To Reduce Seizures In Cardiac Surgery April 8, 2024 Disclosures: TBD
Dr. Martin Maron and Dr. C. Michael Gibson Discuss: Efficacy And Safety Of Ninerafaxstat, A Novel Cardiac Mitotrope, In Patients With Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results Of IMPROVE-HCM April 8, 2024 Disclosures: TBD
Dr. James Januzzi and Dr. C. Michael Gibson Discuss: A Selective Aldose Reductase Inhibitor (at-001) For The Treatment Of Diabetic Cardiomyopathy: Primary Results Of The Phase 3 Randomized Controlled Arise-hf Study April 8, 2024 Disclosures: TBD
